Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Sabina Antonela Antoniu, Ioana Buculei, Florin Mihaltan, Radu Crisan Dabija & Antigona Carmen Trofor. (2021) Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review. Expert Opinion on Pharmacotherapy 22:7, pages 835-847.
Read now
Read now
Seetal Dodd, Lauren Arancini, Nieves Gómez-Coronado, Rudi Gasser, Dan I Lubman, Olivia M Dean & Michael Berk. (2019) Considerations when selecting pharmacotherapy for nicotine dependence. Expert Opinion on Pharmacotherapy 20:3, pages 245-250.
Read now
Read now
Kirsten C. Morley, Andrew Baillie, Wim Van Den Brink, Kate E. Chitty, Kathleen Brady, Sudie E. Back, Devanshi Seth, Greg Sutherland, Lorenzo Leggio & Paul S. Haber. (2018) N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research. Expert Opinion on Investigational Drugs 27:8, pages 667-675.
Read now
Read now
Alessandro Minarini, Silvia Ferrari, Martina Galletti, Nina Giambalvo, Daniela Perrone, Giulia Rioli & Gian Maria Galeazzi. (2017) N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. Expert Opinion on Drug Metabolism & Toxicology 13:3, pages 279-292.
Read now
Read now
Articles from other publishers (46)
Ellen D. Herbst, David L. Pennington, Brian Borsari, Jennifer Manuel, Matthew Yalch, Eric Alcid, Madeline Martinez Rivas, Joannalyn Delacruz, Nathan Rossi, Brianna Garcia, Natalie Wong & Steven L. Batki. (2023) N-acetylcysteine for smoking cessation among dual users of tobacco and cannabis: Protocol and rationale for a randomized controlled trial. Contemporary Clinical Trials 131, pages 107250.
Crossref
Crossref
Kirsten C Morley, Siena Peruch, Claire Adams, Ellen Towers, Chris Tremonti, Joshua Watt, Nazila Jamshidi1 & Paul S Haber. (2023) N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism.
Crossref
Crossref
Shikha Verma. (2023) Substance Use Disorders and Role of Complementary and Integrative Medicine/Functional Medicine. Child and Adolescent Psychiatric Clinics of North America 32:2, pages 217-241.
Crossref
Crossref
Douglas Ziedonis, Cezar Cimpeanu, Amy Bachyrycz, Emily Morelli & Elmars Rancans. 2020. Tasman’s Psychiatry. Tasman’s Psychiatry
1
51
.
Fateme Padoei, Peyman Mamsharifi, Pooya Hazegh, Homa Boroumand, Fatemeh Ostadmohammady, Samira Abbaszadeh‐Mashkani, Hamid Reza Banafshe, Amir Hassan Matini, Amir Ghaderi & Somayeh Ghadami Dehkohneh. (2022) The therapeutic effect of N‐acetylcysteine as an add‐on to methadone maintenance therapy medication in outpatients with substance use disorders: A randomized, double‐blind, placebo‐controlled clinical trial. Brain and Behavior 13:1.
Crossref
Crossref
Norman R. Greenberg, Farzaneh Farhadi, Benjamin Kazer, Marc N. Potenza & Gustavo A. Angarita. (2022) Mechanistic Effects and Use of N-acetylcysteine in Substance Use Disorders. Current Behavioral Neuroscience Reports 9:4, pages 124-143.
Crossref
Crossref
Olga Lucía Murillo-García & Marie Claire Berrouet-Mejía. (2022) La N-acetilcisteína como coadyuvante en el manejo del craving por cocaína y tabaco. Revisión narrativa. Revista de la Facultad de Ciencias de la Salud Universidad del Cauca 24:2, pages 24-31.
Crossref
Crossref
Rishi Sharma, Sai Krishna Tikka, Ashish Ramesh Bhute & Binaya Kumar Bastia. (2022) N-acetyl cysteine in the treatment of cannabis use disorder: A systematic review of clinical trials. Addictive Behaviors 129, pages 107283.
Crossref
Crossref
Richard C. J. Bradlow, Michael Berk, Peter W. Kalivas, Sudie E. Back & Richard A. Kanaan. (2022) The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders. CNS Drugs 36:5, pages 451-482.
Crossref
Crossref
Mauro Porcu, Mariana Ragassi Urbano, Waldiceu A. Verri, Regina Célia Rezende Machado, Heber Odebrecht Vargas & Sandra Odebrecht Vargas Nunes. (2022) Comparison of the severity of depressive and anxiety symptoms, biomarkers, and childhood trauma among bipolar smokers and non-smokers, and controls. Journal of Affective Disorders Reports 8, pages 100336.
Crossref
Crossref
Rusty W. Nall, Lauren N. Beloate, Michael E. Meyerink, Tiffany Penaloza, Jade Doolittle, Brett Froeliger, Peter W. Kalivas & Constanza Garcia‐Keller. (2022)
Assessing combined effects of varenicline and
N
‐acetylcysteine on reducing nicotine seeking in rats
. Addiction Biology 27:2.
Crossref
Crossref
Michael Notaras, Aiman Lodhi, Estibaliz Barrio-Alonso, Careen Foord, Tori Rodrick, Drew Jones, Haoyun Fang, David Greening & Dilek Colak. (2021) Neurodevelopmental signatures of narcotic and neuropsychiatric risk factors in 3D human-derived forebrain organoids. Molecular Psychiatry 26:12, pages 7760-7783.
Crossref
Crossref
Lauren Arancini, Mohammadreza Mohebbi, Michael Berk, Olivia M. Dean, Chiara C. Bortolasci, Briana Spolding, Robson Zazula & Seetal Dodd. (2021) A placebo-controlled, randomised pilot trial of N-acetylcysteine or placebo for cessation of tobacco smoking. European Neuropsychopharmacology 53, pages 120-126.
Crossref
Crossref
Erin E. Maher, Paula F. Overby, Amanda H. Bull, Joshua S. Beckmann, Jonna M. Leyrer-Jackson, Stephanie V. Koebele, Heather A. Bimonte-Nelson & Cassandra D. Gipson. (2021) Natural and synthetic estrogens specifically alter nicotine demand and cue-induced nicotine seeking in female rats. Neuropharmacology 198, pages 108756.
Crossref
Crossref
Irena Smaga, Małgorzata Frankowska & Małgorzata Filip. (2021) N-acetylcysteine in substance use disorder: a lesson from preclinical and clinical research. Pharmacological Reports 73:5, pages 1205-1219.
Crossref
Crossref
Erin A. McClure, Amy E. Wahlquist, Rachel L. Tomko, Nathaniel L. Baker, Matthew J. Carpenter, Elizabeth D. Bradley, Patrick A. Cato, Cassandra D. Gipson & Kevin M. Gray. (2021) Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers. Drug and Alcohol Dependence 225, pages 108815.
Crossref
Crossref
Paul Faulkner, Susanna Lucini Paioni, Petya Kozhuharova, Natasza Orlov, David J. Lythgoe, Yusuf Daniju, Elenor Morgenroth, Holly Barker & Paul Allen. (2020)
Daily and intermittent smoking are associated with low prefrontal volume and low concentrations of prefrontal glutamate, creatine, myo‐inositol, and
N
‐acetylaspartate
. Addiction Biology 26:4.
Crossref
Crossref
Chung-Ting Chang, Pei-Ju Hsieh, Hsin-Chien Lee, Chun-Hong Lo, Ka-Wai Tam & El-Wui Loh. (2021) Effectiveness of N-acetylcysteine in Treating Clinical Symptoms of Substance Abuse and Dependence: A Meta-analysis of Randomized Controlled Trials. Clinical Psychopharmacology and Neuroscience 19:2, pages 282-293.
Crossref
Crossref
María Elena Quintanilla, Paola Morales, Fernando Ezquer, Marcelo Ezquer, Mario Herrera-Marschitz & Yedy Israel. (2021) Administration of N-acetylcysteine Plus Acetylsalicylic Acid Markedly Inhibits Nicotine Reinstatement Following Chronic Oral Nicotine Intake in Female Rats. Frontiers in Behavioral Neuroscience 14.
Crossref
Crossref
Mahtab Zarei, Meysam Zarezadeh, Fateme Khademi, Shaghayegh Adeli, Fateme Abbaszade, Omid Nikpayam, Parisa Janmohammadi, Niyaz Mohammadzadeh Honarvar, Nazanin Hazhir Karzar, Zohreh Ghoreishi & Alireza Ostadrahimi. (2020) What are the effects of N-acetylcysteine supplementation on anthropometric indices? A systematic review and meta-analysis of clinical trials. PharmaNutrition 14, pages 100238.
Crossref
Crossref
Regina C.B.R. Machado, Heber O. Vargas, Marcela M. Baracat, Mariana R. Urbano, Waldiceu A. Verri Jr, Mauro Porcu & Sandra O.V. Nunes. (2020) N-acetylcysteine as an adjunctive treatment for smoking cessation: a randomized clinical trial. Brazilian Journal of Psychiatry 42:5, pages 519-526.
Crossref
Crossref
Ioannis Zalachoras, Fiona Hollis, Eva Ramos-Fernández, Laura Trovo, Sarah Sonnay, Eveline Geiser, Nicolas Preitner, Pascal Steiner, Carmen Sandi & Laia Morató. (2020) Therapeutic potential of glutathione-enhancers in stress-related psychopathologies. Neuroscience & Biobehavioral Reviews 114, pages 134-155.
Crossref
Crossref
Julianna Goenaga, Gregory L. Powell, Jonna M. Leyrer‐Jackson, Jose Piña, Sandy Phan, Alesia V. Prakapenka, Stephanie V. Koebele, Mark D. Namba, Erin A. McClure, Heather A. Bimonte‐Nelson & Cassandra D. Gipson. (2019)
N
‐acetylcysteine yields sex‐specific efficacy for cue‐induced reinstatement of nicotine seeking
. Addiction Biology 25:1.
Crossref
Crossref
Lauren Arancini, Chiara C. Bortolasci, Seetal Dodd, Olivia M. Dean & Michael Berk. (2019) N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial. Trials 20:1.
Crossref
Crossref
Rebecca McKetin, Olivia M. Dean, Alyna Turner, Peter J. Kelly, Brendan Quinn, Dan I. Lubman, Paul Dietze, Gregory Carter, Peter Higgs, Amanda L. Baker, Barbara Sinclair, David Reid, Victoria Manning, Nina te Pas, Wenbin Liang, Tamsin Thomas, Ramez Bathish, Margaret Kent, Dayle Raftery, Shalini Arunogiri, Frank Cordaro, Harry Hill & Michael Berk. (2019) A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine (“ice”) dependence. Trials 20:1.
Crossref
Crossref
Federico Moro, Giuseppe Giannotti, Lucia Caffino, Claudio Marcello Marzo, Angelo Di Clemente, Fabio Fumagalli & Luigi Cervo. (2019) Lasting reduction of nicotine‐seeking behavior by chronic N‐acetylcysteine during experimental cue‐exposure therapy. Addiction Biology, pages e12771.
Crossref
Crossref
Sophie Lebourgeois, María Carmen González-Marín, Johann Antol, Mickael Naassila & Catherine Vilpoux. (2019) Evaluation of N-acetylcysteine on ethanol self-administration in ethanol-dependent rats. Neuropharmacology 150, pages 112-120.
Crossref
Crossref
Pernille Kempel Ellegaard, Rasmus Wentzer Licht, René Ernst Nielsen, Olivia May Dean, Michael Berk, Henrik Enghusen Poulsen, Mohammadreza Mohebbi & Connie Thuroee Nielsen. (2019) The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: A randomized placebo-controlled study. Journal of Affective Disorders 245, pages 1043-1051.
Crossref
Crossref
Tatsuya Nagano, Masahiro Katsurada, Yuichiro Yasuda, Kazuyuki Kobayashi & Yoshihiro Nishimura. (2019) Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials. Therapeutic Advances in Respiratory Disease 13, pages 175346661987592.
Crossref
Crossref
Gregory Powell, Erin A. McClure, M. Foster Olive & Cassandra D. Gipson. 2019. The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine. The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine
219
233
.
Marie N. S. Gendy, Christine Ibrahim, Matthew E. Sloan & Bernard Le Foll. 2020. Substance Use Disorders. Substance Use Disorders
395
420
.
Pernille Kempel Ellegaard, Rasmus Wentzer Licht, Henrik Enghusen Poulsen, René Ernst Nielsen, Michael Berk, Olivia May Dean, Mohammadreza Mohebbi & Connie Thuroee Nielsen. (2018) Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol). International Journal of Bipolar Disorders 6:1.
Crossref
Crossref
Erin A. McClure, Nathaniel L. Baker, Susan C. Sonne, Udi E. Ghitza, Rachel L. Tomko, LaTrice Montgomery, Shanna Babalonis, Garth E. Terry & Kevin M. Gray. (2018) Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study. Drug and Alcohol Dependence 192, pages 59-66.
Crossref
Crossref
Rutuja Yawalkar, Harish Changotra & Girdhari Lal Gupta. (2018) Protective influences of N-acetylcysteine against alcohol abstinence-induced depression by regulating biochemical and GRIN2A, GRIN2B gene expression of NMDA receptor signaling pathway in rats. Neurochemistry International 118, pages 73-81.
Crossref
Crossref
Xue Yang, Yong Wang, Qiyan Li, Yaxian Zhong, Liangpei Chen, Yajun Du, Jing He, Lvshuang Liao, Kun Xiong, Chun-xia Yi & Jie Yan. (2018) The Main Molecular Mechanisms Underlying Methamphetamine- Induced Neurotoxicity and Implications for Pharmacological Treatment. Frontiers in Molecular Neuroscience 11.
Crossref
Crossref
W. Zheng, Q.-E. Zhang, D.-B. Cai, X.-H. Yang, Y. Qiu, G. S. Ungvari, C. H. Ng, M. Berk, Y.-P. Ning & Y.-T. Xiang. (2018)
N
-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials
. Acta Psychiatrica Scandinavica 137:5, pages 391-400.
Crossref
Crossref
Lakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, Ayal Schaffer, David J Bond, Benicio N Frey, Verinder Sharma, Benjamin I Goldstein, Soham Rej, Serge Beaulieu, Martin Alda, Glenda MacQueen, Roumen V Milev, Arun Ravindran, Claire O'Donovan, Diane McIntosh, Raymond W Lam, Gustavo Vazquez, Flavio Kapczinski, Roger S McIntyre, Jan Kozicky, Shigenobu Kanba, Beny Lafer, Trisha Suppes, Joseph R Calabrese, Eduard Vieta, Gin Malhi, Robert M Post & Michael Berk. (2018) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders 20:2, pages 97-170.
Crossref
Crossref
Matthew T. Sutherland & Elliot A. Stein. (2018) Functional Neurocircuits and Neuroimaging Biomarkers of Tobacco Use Disorder. Trends in Molecular Medicine 24:2, pages 129-143.
Crossref
Crossref
Nieves Gómez-Coronado, Adam J. Walker, Michael Berk & Seetal Dodd. (2018) Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:2, pages 235-258.
Crossref
Crossref
Federico Moro, Alessandro Orrù, Claudio Marcello Marzo, Angelo Di Clemente & Luigi Cervo. (2018) mGluR2/3 mediates short-term control of nicotine-seeking by acute systemic N-acetylcysteine. Addiction Biology 23:1, pages 28-40.
Crossref
Crossref
Sade Spencer & Peter W Kalivas. (2017) Glutamate Transport: A New Bench to Bedside Mechanism for Treating Drug Abuse. International Journal of Neuropsychopharmacology 20:10, pages 797-812.
Crossref
Crossref
Rebecca McKetin, Olivia M. Dean, Amanda L. Baker, Greg Carter, Alyna Turner, Peter J. Kelly & Michael Berk. (2017) A potential role for N-acetylcysteine in the management of methamphetamine dependence. Drug and Alcohol Review 36:2, pages 153-159.
Crossref
Crossref
C. J. Perry & A. J. Lawrence. (2017) Addiction, cognitive decline and therapy: seeking ways to escape a vicious cycle. Genes, Brain and Behavior 16:1, pages 205-218.
Crossref
Crossref
Andrew M. Chanen, Michael Berk & Katherine Thompson. (2016) Integrating Early Intervention for Borderline Personality Disorder and Mood Disorders. Harvard Review of Psychiatry 24:5, pages 330-341.
Crossref
Crossref
B. Froeliger, P.A. McConnell, N. Stankeviciute, E.A. McClure, P.W. Kalivas & K.M. Gray. (2015) The effects of N -Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebo-controlled fMRI pilot study. Drug and Alcohol Dependence 156, pages 234-242.
Crossref
Crossref
Deepmala, John Slattery, Nihit Kumar, Leanna Delhey, Michael Berk, Olivia Dean, Charles Spielholz & Richard Frye. (2015) Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neuroscience & Biobehavioral Reviews 55, pages 294-321.
Crossref
Crossref